pyrazines has been researched along with Carcinoma, Transitional Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, Y; Dreicer, R; Emamekhoo, H; Frankel, PH; Hoimes, C; Kim, WY; Lara, PN; Lyou, Y; Michaelson, D; Milowsky, M; Mortazavi, A; Newman, E; Pal, SK; Parikh, M; Parikh, R; Srinivas, S; Teply, B; Vaishampayan, U; Weng, P; Zhang, T | 1 |
| Benedict, W; Dinney, CP; Grossman, HB; Lashinger, L; McConkey, DJ; Millikan, R; Papageorgiou, A | 1 |
| Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ | 1 |
2 trial(s) available for pyrazines and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Isoxazoles; Male; Pyrazines; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms | 2008 |
1 other study(ies) available for pyrazines and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Caspase 8; Caspase Inhibitors; Caspases; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Humans; Interferon Type I; Membrane Glycoproteins; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2004 |